Mertiva AB, formerly Diamyd Medical AB, is a Sweden-based company active within the healthcare sector. As of August 31, 2013, the Company owned 8% shares of the United-States based Protein Sciences Corporation, as well as 19% shares of Mercodia AB. The Company changed its name in May 2013. Additionally, its subsidiary, Diamyd Therapeutics, was spun off and changed its name to Diamyd Medical.

Employees

Sector

Biotechnology & Medical Research

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

28/17/28	Sanofi Pasteur Inc. completed the acquisition of Protein Sciences Corporation from Mertiva AB (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson, Pfizer Inc. and others.	CI
11/17/11	Diamyd Medical and Cardiff University to Collaborate on Study Monitoring Immune Response in Lymph Node Cells After Administration of Diamyd	CI

Market Cap	77Cr 69Cr 64Cr 58Cr 110.01Cr 7.48TCr 111.08Cr 772.64Cr 302.2Cr 3.8TCr 290.04Cr 283.74Cr 12TCr	P/E 2018	28.3x	P/E 2019	13.3x
Enterprise Value	69Cr 62Cr 57Cr 52Cr 98Cr 6.68TCr 99Cr 689.54Cr 269.7Cr 3.39TCr 258.85Cr 253.23Cr 11TCr	EV / Sales 2018	-	EV / Sales 2019	-
Free-Float	68.13%	Yield 2018 *	-	Yield 2019	-

28/17/28	Sanofi Pasteur Inc. completed the acquisition of Protein Sciences Corporation from Mertiva AB (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson, Pfizer Inc. and others.	CI
11/17/11	Diamyd Medical and Cardiff University to Collaborate on Study Monitoring Immune Response in Lymph Node Cells After Administration of Diamyd	CI
11/17/11	Sanofi Pasteur Inc. agreed to acquire Protein Sciences Corporation from Mertiva AB (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson, Pfizer Inc. and others for $750 million	CI
29/15/29	Mertiva AB's Equity Buyback announced on December 6, 2012, has expired.	CI
18/14/18	Mertiva AB (OTCPK:DMYD.F) acquired an additional 0.54% stake in Protein Sciences Corporation for $0.62 million.	CI
22/14/22	Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012.	CI
11/13/11	Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012.	CI
08/13/08	The members of the management of Diamyd, Inc. cancelled the acquisition of 90% stake in Diamyd Inc. from Diamyd Medical AB (OM:DIAM B).	CI
25/13/25	Mertiva AB (OTCPK:DMYD.F) acquired an additional 7.27% stake in Protein Sciences Corporation from Pacific Rim Ventures Co., Ltd. and other shareholders for $8.4 million.	CI
27/13/27	Mertiva AB(NGM:MERT MTF) dropped from OMX Nordic All-Share Index	CI
30/13/30	Mertiva AB(NGM:MERT MTF) dropped from OMX Nordic Small Cap Index	CI
04/13/04	Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012.	CI
23/13/23	Diamyd Medical AB Announces Board Appointments	CI

Date	Insider	Type	Main position	Quantity	% Market Cap.
14/10/20	Sven Håkan Blomdahl	Buy	Chairman	24,314	0.1775%
08/10/20	Sven Håkan Blomdahl	Buy	Chairman	5,378	0.0393%
08/10/20	Sven Håkan Blomdahl	Buy	Chairman	821	0.0060%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MERTIVA AB	-	0.00%	-	-	8.95Cr
WUXI APPTEC CO., LTD.	-3.19%	-3.19%	+44.60%	+87.98%	7.21TCr
ARGENX SE	-15.86%	-16.16%	+2.68%	+50.90%	4.94TCr
LONZA GROUP AG	-2.39%	+0.50%	+3.41%	+31.33%	4.72TCr
REVOLUTION MEDICINES, INC.	-6.35%	-8.63%	+293.39%	+651.28%	4.03TCr
IQVIA HOLDINGS INC.	+0.30%	-0.71%	+29.05%	+30.33%	4.26TCr
BEONE MEDICINES AG	-3.82%	-2.41%	-0.27%	+101.36%	3.98TCr
CELLTRION, INC.	-2.13%	-2.18%	+7.51%	+50.31%	3.05TCr
BIONTECH SE	-3.35%	-4.95%	-13.38%	-17.22%	2.31TCr
GENMAB A/S	-5.27%	+1.86%	+12.19%	-5.34%	2.11TCr
Average	-4.67%	-3.20%	+42.13%	+108.99%	3.66TCr
Weighted average by Cap.	-4.85%	-3.62%	+45.72%	+117.28%

Mertiva AB Share Price

Stocks

MERT A

SE0010023432

Biotechnology & Medical Research

Valuation: Mertiva AB

Latest news: Mertiva AB

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

	2018	2019
Net sales	-	-
Net income	2.53Cr 2.26Cr 2.11Cr 1.91Cr 3.6Cr 245.02Cr 3.64Cr 25Cr 9.9Cr 124.51Cr 9.5Cr 9.29Cr 400.42Cr	7.7Cr 6.88Cr 6.41Cr 5.83Cr 11Cr 745.67Cr 11Cr 77Cr 30Cr 378.91Cr 29Cr 28Cr 1.22TCr
Net Debt	-25Cr -23Cr -21Cr -19Cr -36Cr -2.45TCr -36Cr -252.9Cr -99Cr -1.24TCr -95Cr -93Cr -4TCr	-8.31Cr -7.42Cr -6.92Cr -6.29Cr -12Cr -804.61Cr -12Cr -83Cr -32Cr -408.86Cr -31Cr -31Cr -1.31TCr

End-of-day quote NORDIC GROWTH MARKET
- ^SEK	-